-
Mashup Score: 2
Daniel Rubin, PharmD, BCOP, discussed a study showing how a clinical decision support tool can improve the documentation of biomarker results in cancer care.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Amar Kishan, MD, shares 2-year data on MRI-guided vs CT-guided SBRT - 10 hour(s) ago
“Physician scored GU toxicity grade 2 or greater at 2 years was 51% with the CT-guided and 27% with the MRI-guided,” says Amar U. Kishan, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Amar U. Kishan, MD, (@AmarUKishan) shares 2-year outcomes from the MIRAGE trial, which compared toxicity of aggressive margin reduction with MRI-guided SBRT to that of CT-guided SBRT for prostate cancer. @UclaUrology #pcsm https://t.co/EXYZz6uHdM
-
-
Mashup Score: 0
The primary end point is 12-month radiographic progression-free survival.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
A phase 2 trial has been initiated to explore the combination of opaganib and darolutamide in patients with mCRPC. #pcsm https://t.co/Roe69fXIj1
-
-
Mashup Score: 5
In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients with metastatic hormone-sensitive prostate cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients with metastatic hormone-sensitive prostate cancer. #pcsm https://t.co/HfBfG1mZFM
-
-
Mashup Score: 0
“We need to think carefully about what we’re putting in our body and what the regulations are about natural products that we ingest,” says Channing J. Paller, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Channing J. Paller, MD, (@Cpaller) discusses challenges in translating preclinical results of natural products into successful clinical trials for prostate cancer. #pcsm @brady_urology https://t.co/YXvdeUrqsY
-
-
Mashup Score: 1
“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers,” says Ganesh S. Palapattu, MD, FACS.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The MyProstateScore 2.0 test demonstrated high sensitivity in the detection of grade group 2 or higher prostate cancer using first-catch, non-DRE urine. #pcsm @gpalapa2 @UMichUrology Learn more: https://t.co/vGL2qjDTWE
-
-
Mashup Score: 11
“It does seem clear that we need to get back to a smarter middle ground of screening—using screening more intelligently, finding the high-grade cancers and treating them—so that we can get that mortality curve back on a downward trajectory,” says Matthew R. Cooperberg, MD, MPH.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Matthew Cooperberg, MD, (@dr_coops) highlights key prostate cancer data from the American Cancer Society’s (@AmericanCancer) Cancer Statistics, 2025 report. @UCSFUrology #pcsm https://t.co/dQ7O5wUQe6
-
-
Mashup Score: 1
“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers,” says Ganesh S. Palapattu, MD, FACS.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The MyProstateScore 2.0 test demonstrated high sensitivity in the detection of grade group 2 or higher prostate cancer using first-catch, non-DRE urine. #pcsm @gpalapa2 @UMichUrology Learn more: https://t.co/vGL2qjDTWE
-
-
Mashup Score: 1
WNT9B E152K was associated with a 2.5-fold increase in the risk of prostate cancer and reached genome-wide significance.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
A recent study conducted by investigators at @VUMCurology found that pathogenic variants of the WNT9B gene were associated with an increased risk of hereditary prostate cancer. #pcsm Read more: https://t.co/T3eAfduD23
-
-
Mashup Score: 4Amar Kishan, MD, outlines the rationale for the MIRAGE trial - 7 day(s) ago
“The trial was specifically looking at whether that aggressive margin reduction from 4 mm to 2 mm would lead to a reduction in physician-reported urinary toxicity, specifically in the first 90 days after radiation,” says Amar U. Kishan, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
WATCH: Amar U. Kishan, MD, (@AmarUKishan) discusses the rationale for the initiation and design of the MIRAGE trial. @UclaUrology #pcsm https://t.co/JbNhZT34Nk
-
In an interview, Daniel Rubin, PharmD, BCOP, discussed a study showing how a clinical decision support tool can improve the documentation of biomarker results in cancer care. #pcsm | @TheUSONetwork https://t.co/TRU3u35Khd https://t.co/JBkhyowSaX